Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04316351 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

Interventions

DRUG: Toripalimab + Pemetrexed + Anlotinib

Sponsor

Guangzhou Institute of Respiratory Disease

Collaborators

[object Object]